

Combination Treatment for Improved Cancer Therapy

Published date: Oct. 22, 2013

Technology description

Unique compounds for use in cancer therapeutics.

Treatment involving these compounds have shown strong synergistic cytotoxicity on colon and pancreatic cancer cells that were relatively resistant to the treatment with FU alone. Such a combination could prove to be significantly more potent than previous treatment options and at a lower risk to the patient.

Background

The search for effective cancer therapeutics remains a hot topic on modern healthcare's agenda. Various treatments have emerged in the hopes of countering a wide variety of cancer types. Since 1957, 5-fluorouracil (FU) has been used as a chemotherapy reagent for colorectal, breast, pancreatic, and other types of cancers. Over time, many derivatives of FU and combination therapies with other drugs have been developed and tested for effectiveness. These derivatives and combinations have proven useful in numerous instances, but there are still many other tumor types that show very little response or even exhibit resistance to FU-related treatments. The search for improved anti-cancer regimens capable of treating cancer (in general), especially resistant cancer types, has continued ever since.

Technology Description

Researchers at the University of New Mexico have developed a unique combination of compounds for use in cancer therapeutics. Treatment involving these compounds have shown strong synergistic cytotoxicity on colon and pancreatic cancer cells that were relatively resistant to the treatment with FU alone. Such a combination could prove to be significantly more potent than previous treatment options and at a lower risk to the patient.

Application area

A novel cancer therapeutic that may prove effective in the treatment of resistant cancer types

A combination of compounds that shows the same level of effectiveness as previous treatment options, but at a lower concentration

Improved treatment safety for patients

Lowered costs of treatment, for hospitals and patients alike

Institution

[The University of New Mexico](#)

Inventors

[Alan Tomkinson](#)

[Yoshihiro Matsumoto](#)

[Hiroshi Ide](#)

联系我们



叶先生

电话 : 021-65679356

手机 : 13414935137

邮箱 : yeyingsheng@zf-ym.com